GPCR Structure Therapeutics Inc.
USHealthcareAs of 2026-07-08 16:00
Why GPCR matters now
Structure Therapeutics Inc. (GPCR) is a US stock in Healthcare. The latest InvestLog snapshot shows $54.89 with -3.07% on the session and $3.16B in market capitalization; recent performance reads 1-month +24.05% and YTD -36.00%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-76.2M, and EPS of $-1.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -6.2%.
The latest indexable market news headline is "The Next Phase Of The Obesity Drug Race" from CNBC.
Additional event context on this page matters because analyst consensus is Buy with a median target of $102.00; recent insider activity includes WELCH DANIEL G filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.23
P/S
0.00
EV/EBITDA
-13.42
DCF Value
$13.18
FCF Yield
-6.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-15.1%
ROA
-11.3%
ROIC
-14.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-76.2M | $-1.05 |
| Q4 2025 | $0.00 | $33.0M | $0.60 |
| FY 2025 | $0.00 | $-141.2M | $-2.40 |
| Q3 2025 | $0.00 | $-65.7M | $-1.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$111.60
Target (Median)
$102.00
Target Range
$70.00 - $145.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-1.42
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.